Cargando…
All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846739/ https://www.ncbi.nlm.nih.gov/pubmed/33514684 http://dx.doi.org/10.1038/s41408-021-00411-9 |
| _version_ | 1783644793024282624 |
|---|---|
| author | Zhang, Xinhui Feng, Shanglong Xu, Jin Zhao, Na Hu, Xing Zhou, Li Tong, Juan Xue, Lei Zhang, Lei Han, Yongsheng Wang, Xingbing Geng, Liangquan Zhu, Xiaoyu Tang, Baolin Liu, Huilan Zhu, Weibo Cai, Xiaoyan Liu, Xin Sun, Zimin Zheng, Changcheng |
| author_facet | Zhang, Xinhui Feng, Shanglong Xu, Jin Zhao, Na Hu, Xing Zhou, Li Tong, Juan Xue, Lei Zhang, Lei Han, Yongsheng Wang, Xingbing Geng, Liangquan Zhu, Xiaoyu Tang, Baolin Liu, Huilan Zhu, Weibo Cai, Xiaoyan Liu, Xin Sun, Zimin Zheng, Changcheng |
| author_sort | Zhang, Xinhui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7846739 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78467392021-02-11 All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting Zhang, Xinhui Feng, Shanglong Xu, Jin Zhao, Na Hu, Xing Zhou, Li Tong, Juan Xue, Lei Zhang, Lei Han, Yongsheng Wang, Xingbing Geng, Liangquan Zhu, Xiaoyu Tang, Baolin Liu, Huilan Zhu, Weibo Cai, Xiaoyan Liu, Xin Sun, Zimin Zheng, Changcheng Blood Cancer J Correspondence Nature Publishing Group UK 2021-01-29 /pmc/articles/PMC7846739/ /pubmed/33514684 http://dx.doi.org/10.1038/s41408-021-00411-9 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Zhang, Xinhui Feng, Shanglong Xu, Jin Zhao, Na Hu, Xing Zhou, Li Tong, Juan Xue, Lei Zhang, Lei Han, Yongsheng Wang, Xingbing Geng, Liangquan Zhu, Xiaoyu Tang, Baolin Liu, Huilan Zhu, Weibo Cai, Xiaoyan Liu, Xin Sun, Zimin Zheng, Changcheng All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| title | All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| title_full | All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| title_fullStr | All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| title_full_unstemmed | All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| title_short | All-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| title_sort | all-trans retinoic acid 45 mg/m(2) is superior to 25 mg/m(2) as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846739/ https://www.ncbi.nlm.nih.gov/pubmed/33514684 http://dx.doi.org/10.1038/s41408-021-00411-9 |
| work_keys_str_mv | AT zhangxinhui alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT fengshanglong alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT xujin alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT zhaona alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT huxing alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT zhouli alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT tongjuan alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT xuelei alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT zhanglei alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT hanyongsheng alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT wangxingbing alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT gengliangquan alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT zhuxiaoyu alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT tangbaolin alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT liuhuilan alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT zhuweibo alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT caixiaoyan alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT liuxin alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT sunzimin alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting AT zhengchangcheng alltransretinoicacid45mgm2issuperiorto25mgm2asthefirstinductionregimenforthetreatmentofacutepromyelocyticleukaemiaaretrospectiveanalysisinarealworldclinicalsetting |